» Articles » PMID: 30037856

Elevated MiR-182-5p Associates with Renal Cancer Cell Mitotic Arrest Through Diminished Expression

Abstract

The molecular heterogeneity of clear cell renal carcinoma (ccRCC) makes prediction of disease progression and therapeutic response difficult. Thus, this report investigates the functional significance, mechanisms of action, and clinical utility of miR-182-5p and metastasis-associated lung adenocarcinoma transcript 1 (), a long noncoding RNA (lncRNA), in the regulation of kidney cancer using human kidney cancer tissues as well as and model systems. Profiling of miR-182-5p and in human renal cancer cells and clinical specimens was done by quantitative real-time PCR (qPCR). The biological significance was determined by series of and experiments. The interaction between miR-182-5p and was investigated using luciferase reporter assays. In addition, the effects of miR-182-5p overexpression and downregulation on cell-cycle progression were assessed in ccRCC cells. The data indicate that miR-182-5p is downregulated in ccRCC; the mechanism being CpG hypermethylation as observed from 5-Aza CdR treatment that decreased promoter methylation and expression of key methylation regulatory genes like , and Overexpression of miR-182-5p-inhibited cell proliferation, colony formation, apoptosis, and led to G-M-phase cell-cycle arrest by directly targeting Downregulation of led to upregulation of p53, downregulation of CDC20, AURKA, drivers of the cell-cycle mitotic phase. Transient knockdown of mimicked the effects of miR-182-5p overexpression. Finally, overexpression of miR-182-5p decreased tumor growth in mice, compared with controls; thus, demonstrating its antitumor effect This is the first study that offers new insight into role of miR-182-5p/ interaction on inhibition of ccRCC progression. .

Citing Articles

Targeting microRNA methylation: Innovative approaches to diagnosing and treating hepatocellular carcinoma.

Sufianov A, Agaverdiev M, Mashkin A, Ilyasova T Noncoding RNA Res. 2025; 11():150-157.

PMID: 39829957 PMC: 11742574. DOI: 10.1016/j.ncrna.2024.12.002.


The ncRNA-AURKA Interaction in Hepatocellular Carcinoma: Insights into Oncogenic Pathways, Therapeutic Opportunities, and Future Challenges.

Garcia C, Grisetti L, Tiribelli C, Pascut D Life (Basel). 2024; 14(11).

PMID: 39598228 PMC: 11595987. DOI: 10.3390/life14111430.


Identification of fibrosis-associated biomarkers in heart failure and human cancers.

Hou C, Huo J, Yan S, Sun F, Yang X J Transl Med. 2024; 22(1):1042.

PMID: 39563337 PMC: 11575019. DOI: 10.1186/s12967-024-05759-7.


The functions of long non-coding RNA (lncRNA)-MALAT-1 in the pathogenesis of renal cell carcinoma.

Anbiyaee O, Moalemnia A, Ghaedrahmati F, Khombi Shooshtari M, Khoshnam S, Kempisty B BMC Nephrol. 2023; 24(1):380.

PMID: 38124072 PMC: 10731893. DOI: 10.1186/s12882-023-03438-1.


The potential role of CDC20 in tumorigenesis, cancer progression and therapy: A narrative review.

Xian F, Zhao C, Huang C, Bie J, Xu G Medicine (Baltimore). 2023; 102(36):e35038.

PMID: 37682144 PMC: 10489547. DOI: 10.1097/MD.0000000000035038.


References
1.
Diez-Villanueva A, Mallona I, Peinado M . Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenetics Chromatin. 2015; 8:22. PMC: 4480445. DOI: 10.1186/s13072-015-0014-8. View

2.
Nip H, Dar A, Saini S, Colden M, Varahram S, Chowdhary H . Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget. 2016; 7(42):68371-68384. PMC: 5356562. DOI: 10.18632/oncotarget.12031. View

3.
Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai Z . Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res. 2015; 75(7):1322-31. PMC: 5884967. DOI: 10.1158/0008-5472.CAN-14-2931. View

4.
Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

5.
Sasai K, Treekitkarnmongkol W, Kai K, Katayama H, Sen S . Functional Significance of Aurora Kinases-p53 Protein Family Interactions in Cancer. Front Oncol. 2016; 6:247. PMC: 5122578. DOI: 10.3389/fonc.2016.00247. View